Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS p.Gln61Lys (p.Q61K)
(
ENST00000369535.5 )
NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2907
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/427
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Trametinib,Selumetinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23515407
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Sensitivity | true |
| Trametinib | Sensitivity | true |